PEPTIDE
Verified ComparisonLast updated: 29 March 2026

Tesofensine vs Liraglutide

Tesofensine activates CNS monoamine systems; Liraglutide is an approved GLP-1 agonist. Both studied in weight-loss research.

Compound A

Tesofensine

Metabolic

Evidence
3.8/ 5
B+

Compound B

Liraglutide

Metabolic

Evidence
4.2/ 5
A−
Editor's note
Liraglutide is approved; Tesofensine showed higher weight loss but development halted.
CriterionTesofensineLiraglutide
MechanismCNS monoamine reuptakeGLP-1 receptor agonism
Weight loss magnitudeVery high (trials)Substantial (approved)
Regulatory approvalDevelopment haltedApproved
Safety clarityConcerns emergedEstablished
Clinical adoptionNoneWidespread

Frequently asked questions

Approval, established safety, and clinical experience outweigh tesofensine's higher weight-loss potential.